Tags

Type your tag names separated by a space and hit enter

Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
J Am Coll Cardiol. 2016 10 25; 68(17):1823-1834.JACC

Abstract

BACKGROUND

Impaired functional capacity is a hallmark of patients with heart failure with preserved ejection fraction (HFpEF). Despite the association of HFpEF with reduced myocardial compliance attributed to fibrosis, spironolactone has not been shown to alter outcomes-perhaps reflecting the heterogeneity of underlying pathological mechanisms.

OBJECTIVES

The authors sought to identify improvement in exercise capacity with spironolactone in the subset of patients with HFpEF with exercise-induced increase in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e') reflecting elevation of left ventricular (LV) filling pressure.

METHODS

In this randomized, blinded, parallel-group, placebo-controlled trial, 150 subjects (age 67 ± 9 years) with exertional dyspnea (New York Heart Association functional class II to III, left ventricular ejection fraction >50%, diastolic dysfunction, and exertional E/e' >13), excluding those with ischemic heart disease, were recruited in a tertiary cardiology center. Patients were randomized to 6 months of oral spironolactone 25 mg/day or matching placebo. Primary outcomes were improvements in peak oxygen uptake (VO2) and exertional E/e' ratio, and secondary outcomes were improvements in exercise blood pressure response and global LV longitudinal strain.

RESULTS

At follow-up, 131 patients completed therapy-64 taking spironolactone and 67 placebo. At baseline, subjects had substantial exercise limitation (peak VO2 64 ± 17% predicted). The spironolactone group showed improvement in exercise capacity (increment in peak VO2 [2.9 ml/min/kg (95% confidence interval [CI]: 1.9 to 3.9 ml/min/kg) vs. 0.3 ml/min/kg (95% CI: -0.5 to 1.1 ml/min/kg); p < 0.001], anaerobic threshold [2.0 ml/min/kg (95% CI: 0.9 to 3.2 ml/min/kg) vs. -0.9 ml/min/kg (95% CI: -3.4 to 1.6 ml/min/kg); p = 0.03], and O2 uptake efficiency [0.19 (95% CI: 0.06 to 0.31) vs. -0.07 (95% CI: -0.17 to 0.04); p = 0.002]), with reduction in exercise-induced increase in E/e' (-3.0 [95% CI: -3.9 to -2.0] vs. 0.5 [95% CI: -0.6 to 1.6]; p < 0.001). There was a significant interaction of spironolactone and change in E/e' on VO2 (p = 0.039).

CONCLUSIONS

In patients with HFpEF and abnormal diastolic response to exertion, improvement in exercise E/e' mediates the beneficial effect of spironolactone on exercise capacity. Identification of exercise-induced increase in LV filling pressure in patients with HFpEF may define a subgroup with warranting trial of spironolactone.

Authors+Show Affiliations

Cardiology Department, Wroclaw Medical University, Wroclaw, Poland; Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Baker IDI Heart and Diabetes Institute, Melbourne, Australia.Cardiology Department, Wroclaw Medical University, Wroclaw, Poland.Cardiology Department, Wroclaw Medical University, Wroclaw, Poland; Baker IDI Heart and Diabetes Institute, Melbourne, Australia.Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Baker IDI Heart and Diabetes Institute, Melbourne, Australia.Cardiology Department, Wroclaw Medical University, Wroclaw, Poland.Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Baker IDI Heart and Diabetes Institute, Melbourne, Australia. Electronic address: tom.marwick@bakeridi.edu.au.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27765184

Citation

Kosmala, Wojciech, et al. "Effect of Aldosterone Antagonism On Exercise Tolerance in Heart Failure With Preserved Ejection Fraction." Journal of the American College of Cardiology, vol. 68, no. 17, 2016, pp. 1823-1834.
Kosmala W, Rojek A, Przewlocka-Kosmala M, et al. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2016;68(17):1823-1834.
Kosmala, W., Rojek, A., Przewlocka-Kosmala, M., Wright, L., Mysiak, A., & Marwick, T. H. (2016). Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 68(17), 1823-1834. https://doi.org/10.1016/j.jacc.2016.07.763
Kosmala W, et al. Effect of Aldosterone Antagonism On Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2016 10 25;68(17):1823-1834. PubMed PMID: 27765184.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. AU - Kosmala,Wojciech, AU - Rojek,Aleksandra, AU - Przewlocka-Kosmala,Monika, AU - Wright,Leah, AU - Mysiak,Andrzej, AU - Marwick,Thomas H, PY - 2016/04/28/received PY - 2016/07/19/revised PY - 2016/07/20/accepted PY - 2016/10/22/pubmed PY - 2017/6/29/medline PY - 2016/10/22/entrez KW - aldosterone antagonism KW - echocardiography KW - heart failure with preserved ejection fraction KW - left ventricular filling pressure SP - 1823 EP - 1834 JF - Journal of the American College of Cardiology JO - J. Am. Coll. Cardiol. VL - 68 IS - 17 N2 - BACKGROUND: Impaired functional capacity is a hallmark of patients with heart failure with preserved ejection fraction (HFpEF). Despite the association of HFpEF with reduced myocardial compliance attributed to fibrosis, spironolactone has not been shown to alter outcomes-perhaps reflecting the heterogeneity of underlying pathological mechanisms. OBJECTIVES: The authors sought to identify improvement in exercise capacity with spironolactone in the subset of patients with HFpEF with exercise-induced increase in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e') reflecting elevation of left ventricular (LV) filling pressure. METHODS: In this randomized, blinded, parallel-group, placebo-controlled trial, 150 subjects (age 67 ± 9 years) with exertional dyspnea (New York Heart Association functional class II to III, left ventricular ejection fraction >50%, diastolic dysfunction, and exertional E/e' >13), excluding those with ischemic heart disease, were recruited in a tertiary cardiology center. Patients were randomized to 6 months of oral spironolactone 25 mg/day or matching placebo. Primary outcomes were improvements in peak oxygen uptake (VO2) and exertional E/e' ratio, and secondary outcomes were improvements in exercise blood pressure response and global LV longitudinal strain. RESULTS: At follow-up, 131 patients completed therapy-64 taking spironolactone and 67 placebo. At baseline, subjects had substantial exercise limitation (peak VO2 64 ± 17% predicted). The spironolactone group showed improvement in exercise capacity (increment in peak VO2 [2.9 ml/min/kg (95% confidence interval [CI]: 1.9 to 3.9 ml/min/kg) vs. 0.3 ml/min/kg (95% CI: -0.5 to 1.1 ml/min/kg); p < 0.001], anaerobic threshold [2.0 ml/min/kg (95% CI: 0.9 to 3.2 ml/min/kg) vs. -0.9 ml/min/kg (95% CI: -3.4 to 1.6 ml/min/kg); p = 0.03], and O2 uptake efficiency [0.19 (95% CI: 0.06 to 0.31) vs. -0.07 (95% CI: -0.17 to 0.04); p = 0.002]), with reduction in exercise-induced increase in E/e' (-3.0 [95% CI: -3.9 to -2.0] vs. 0.5 [95% CI: -0.6 to 1.6]; p < 0.001). There was a significant interaction of spironolactone and change in E/e' on VO2 (p = 0.039). CONCLUSIONS: In patients with HFpEF and abnormal diastolic response to exertion, improvement in exercise E/e' mediates the beneficial effect of spironolactone on exercise capacity. Identification of exercise-induced increase in LV filling pressure in patients with HFpEF may define a subgroup with warranting trial of spironolactone. SN - 1558-3597 UR - https://www.unboundmedicine.com/medline/citation/27765184/Effect_of_Aldosterone_Antagonism_on_Exercise_Tolerance_in_Heart_Failure_With_Preserved_Ejection_Fraction_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(16)34964-6 DB - PRIME DP - Unbound Medicine ER -